Loading...
•
Jun 30, 2021
Corbus Pharmaceuticals Q2 2021 Earnings Report
Corbus Pharmaceuticals reported financial results for the second quarter of 2021 and provided corporate updates.
Key Takeaways
Corbus Pharmaceuticals reported revenue from awards and licenses of $137,000 for the second quarter of 2021. Operating expenses decreased by $21.6 million to $16.8 million. The company reported a net loss of $17.1 million, or a net loss per diluted share of $0.15.
Corbus is expanding its pipeline by licensing two integrin-targeting mAbs.
The company is on track to progress these assets along with its small molecules into the clinic next year.
Corbus has a strong financial position with approximately $114M of cash and investments on hand.
A refundable foreign tax credit of approximately $12.2 million was received subsequent to June 30th.